These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15990988)

  • 1. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S; Girndt M; Köhler H
    Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W
    MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
    [No Abstract]   [Full Text] [Related]  

  • 4. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
    MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
    Barnett AH
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
    Rippin J; Bain SC; Barnett AH;
    J Diabetes Complications; 2002; 16(3):195-200. PubMed ID: 12015188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan vs. enalapril in type 2 diabetes.
    Loewenstein JE
    N Engl J Med; 2005 Feb; 352(8):835-6; author reply 835-6. PubMed ID: 15736291
    [No Abstract]   [Full Text] [Related]  

  • 9. Telmisartan vs. enalapril in type 2 diabetes.
    Asgari AA; Sarvghadi F; Zahed N
    N Engl J Med; 2005 Feb; 352(8):835-6; author reply 835-6. PubMed ID: 15728820
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.
    Smith DH
    Clin Ther; 2002 Oct; 24(10):1484-501. PubMed ID: 12462282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [INNOVATION study].
    Ogawa D; Makino H
    Nihon Rinsho; 2010 Nov; 68 Suppl 9():451-4. PubMed ID: 21667499
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure.
    Nakamura T; Sugaya T; Koide H
    Diabetologia; 2007 Feb; 50(2):490-2. PubMed ID: 17171364
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
    Sengul AM; Altuntas Y; Kürklü A; Aydin L
    Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan vs. enalapril in type 2 diabetes.
    Parving HH; Hovind P; Rossing P
    N Engl J Med; 2005 Feb; 352(8):835-6; author reply 835-6. PubMed ID: 15736292
    [No Abstract]   [Full Text] [Related]  

  • 20. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.